MRI contrast developer Epix Pharmaceuticals of Lexington, MA, said its chairman, Christopher Gabrieli, is retiring.
Gabrieli was an early investor in Epix and has provided the company with invaluable counsel over the years, according to the firm. His position as chairman on the board will be filled by Frederick Frank, currently an Epix board member.
By AuntMinnie.com staff writers
May 2, 2007
Related Reading
Epix regains Nasdaq compliance, April 13, 2007
Epix Pharma says decision on contrast agent may take longer, April 3, 2007
Epix files formal appeal for Vasovist, February 28, 2007
Epix to restate past financial reports, February 26, 2007
Epix files U.S. Vasovist appeal, December 15, 2006
Copyright © 2007 AuntMinnie.com